Abstract

The world is becoming overwhelmed with widespread diseases as antibiotic resistance increases at an alarming rate. Hence, there is a demanding need for the discovery and development of new antimicrobial drugs. The ocean is gifted with many organisms like phytoplankton, algae, sponges, cnidarians, bryozoans, mollusk, tunicates and echinoderms, which are known to produce a wide variety of bioactive secondary metabolites with pharmacological properties. Many new therapeutic drugs have emerged from marine invertebrates, although the large algal community is yet to be explored. The bioactivity possessing secondary metabolites of marine algae include polyphenols, phlorotannins, alkaloids, halogenated compounds, sulfated polysaccharides, agar, carrageenan, proteoglycans, alginate, laminaran, rhamnan sulfate, galactosylglycerol, and fucoidan. These metabolites have been found to have great antimicrobial activities against many human aliments. Studies show that the algal community represents about 9% of biomedical compounds obtained from the sea. This review looks at the evolution of drugs from the ocean, with a special emphasis on the antimicrobial activities of marine algae.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call